Table of Contents Author Guidelines Submit a Manuscript
International Journal of Breast Cancer
Volume 2011, Article ID 523276, 8 pages
http://dx.doi.org/10.4061/2011/523276
Research Article

Obesity Is an Independent Predictor of Poor Survival in Metastatic Breast Cancer: Retrospective Analysis of a Patient Cohort Whose Treatment Included High-Dose Chemotherapy and Autologous Stem Cell Support

1Division of Hematology/Oncology, Department of Medicine, UCSD, CA 92093, USA
2Moores Cancer Center, 3855 Health Sciences Drive, La Jolla, Ca 92093-0829, USA
3Division of Biostatistics and Bioinformatics, Department of Family and Preventive Medicine, UCSD, CA 92093, USA
4Division of Bone and Marrow Transplantation, Department of Medicine, UCSD, CA 92093, USA

Received 4 April 2011; Accepted 5 May 2011

Academic Editor: Filippo Montemurro

Copyright © 2011 A. von Drygalski et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. Tai, E. Yu, V. Vinh-Hung, G. Cserni, and G. Vlastos, “Survival of patients with metastatic breast cancer: twenty-year data from two SEER registries,” BMC Cancer, vol. 4, article 60, 2004. View at Publisher · View at Google Scholar · View at PubMed
  2. N. Wilcken and R. Dear, “Chemotherapy in metastatic breast cancer: a summary of all randomised trials reported 2000–2007,” European Journal of Cancer, vol. 44, no. 15, pp. 2218–2225, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  3. C. E. Geyer, J. Forster, D. Lindquist et al., “Lapatinib plus capecitabine for HER2-positive advanced breast cancer,” New England Journal of Medicine, vol. 355, no. 26, pp. 2733–2743, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  4. K. Miller, M. Wang, J. Gralow et al., “Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer,” New England Journal of Medicine, vol. 357, no. 26, pp. 2666–2676, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  5. D. J. Slamon, B. Leyland-Jones, S. Shak et al., “Use of chemotherapy plus a monoclonal antibody against her2 for metastatic breast cancer that overexpresses HER2,” New England Journal of Medicine, vol. 344, no. 11, pp. 783–792, 2001. View at Publisher · View at Google Scholar · View at Scopus
  6. R. Abraham, T. Nagy, P. E. Goss, and M. Crump, “High dose chemotherapy and autologous blood stem cell support in women with breast carcinoma and isolated supraclavicular lymph node metastases,” Cancer, vol. 88, no. 4, pp. 790–795, 2000. View at Publisher · View at Google Scholar · View at Scopus
  7. K. Antman, L. Ayash, A. Elias et al., “High-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy: analysis by age,” Journal of the National Cancer Institute. Monographs, no. 16, pp. 91–94, 1994. View at Google Scholar
  8. L. J. Ayash, A. Elias, C. Wheeler et al., “Double dose-intensive chemotherapy with autologous marrow and peripheral- blood progenitor-cell support for metastatic breast cancer: a feasibility study,” Journal of Clinical Oncology, vol. 12, no. 1, pp. 37–44, 1994. View at Google Scholar · View at Scopus
  9. C. Gisselbrecht, J. M. Extra, J. P. Lotz et al., “Cyclophosphamide/mitoxantrone/melphalan (CMA) regimen prior to autologous bone marrow transplantation (ABMT) in metastatic breast cancer,” Bone Marrow Transplantation, vol. 18, no. 5, pp. 857–863, 1996. View at Google Scholar
  10. N. Kröger, M. Frick, O. Gluz et al., “Randomized trial of single compared with tandem high-dose chemotherapy followed by autologous stem-cell transplantation in patients with chemotherapy-sensitive metastatic breast cancer,” Journal of Clinical Oncology, vol. 24, no. 24, pp. 3919–3926, 2006. View at Publisher · View at Google Scholar · View at PubMed
  11. J. -P. Lotz, H. Curé, M. Janvier et al., “High-dose chemotherapy with haematopoietic stem cell transplantation for metastatic breast cancer patients: final results of the French multicentric randomised CMA/PEGASE 04 protocol,” European Journal of Cancer, vol. 41, no. 1, pp. 71–80, 2005. View at Publisher · View at Google Scholar · View at PubMed
  12. P. Schmid, W. Schippinger, T. Nitsch, G. Huebner, R. Kreienberg, and W. Schultze, “Up-front tandem high-dose chemotherapy (HD) compared to standard chemotherapy with doxorubicin and paclitaxel (AT) in metastatic breast cancer (MBC): final results of a randomized trial,” Journal of Clinical Oncology, vol. 22, p. 37S, 2004. View at Google Scholar
  13. J. J. Vredenburgh, B. Madan, D. Coniglio et al., “A randomized phase III comparative trial of immediate consolidation with high-dose chemotherapy and autologous peripheral blood progenitor cell support compared to observation with delayed consolidation in women with metastatic breast cancer and only bone metastases following intensive induction chemotherapy,” Bone Marrow Transplantation, vol. 37, no. 11, pp. 1009–1015, 2006. View at Publisher · View at Google Scholar · View at PubMed
  14. J. J. Vredenburgh, D. Coniglio, G. Broadwater et al., “Consolidation with high-dose combination alkylating agents with bone marrow transplantation significantly improves disease-free survival in hormone-insensitive metastatic breast cancer in complete remission compared with intensive standard-dose chemotherapy alone,” Biology of Blood and Marrow Transplantation, vol. 12, no. 2, pp. 195–203, 2006. View at Publisher · View at Google Scholar · View at PubMed
  15. M. Crump, S. Gluck, D. Tu et al., “Randomized trial of high-dose chemotherapy with autologous peripheral-blood stem-cell support compared with standard-dose chemotherapy in women with metastatic breast cancer: NCIC MA.16,” Journal of Clinical Oncology, vol. 26, no. 1, pp. 37–43, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  16. E. A. Diaz-Canton, V. Valero, Z. Rahman et al., “Clinical course of breast cancer patients with metastases confined to the lungs treated with chemotherapy,” Annals of Oncology, vol. 9, no. 4, pp. 413–418, 1998. View at Publisher · View at Google Scholar · View at Scopus
  17. O. Er, D. K. Frye, S. -W.C. Kau et al., “Clinical course of breast cancer patients with metastases limited to the liver treated with chemotherapy,” Cancer Journal, vol. 14, no. 1, pp. 62–68, 2008. View at Publisher · View at Google Scholar · View at PubMed
  18. P. A. C. Greenberg, G. N. Hortobagyi, T. L. Smith, L. D. Ziegler, D. K. Frye, and A. U. Buzdar, “Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer,” Journal of Clinical Oncology, vol. 14, no. 8, pp. 2197–2205, 1996. View at Google Scholar · View at Scopus
  19. U. Güth, D. J. Huang, S. Dirnhofer, C. Rochlitz, and E. Wight, “Distant metastatic breast cancer as an incurable disease: a tenet with a need for revision,” Cancer Journal, vol. 15, no. 1, pp. 81–86, 2009. View at Google Scholar
  20. G. N. Hortobagyi, “Can we cure limited metastatic breast cancer?” Journal of Clinical Oncology, vol. 20, no. 3, pp. 620–623, 2002. View at Google Scholar
  21. Jr. Sledge G.W., “Should we dream the impossible dream? The meaning of long-term survival in metastatic breast cancer,” Journal of Clinical Oncology, vol. 14, no. 8, pp. 2191–2193, 1996. View at Google Scholar
  22. K. H. Antman, P. A. Rowlings, W. P. Vaughan et al., “High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America,” Journal of Clinical Oncology, vol. 15, no. 5, pp. 1870–1879, 1997. View at Google Scholar
  23. A. D. Elias, J. Ibrahim, P. Richardson et al., “The impact of induction duration and the number of high-dose cycles on the long-term survival of women with metastatic breast cancer treated with high-dose chemotherapy with stem cell rescue: an analysis of sequential phase I/II trials from the Dana-Farber/Beth Israel STAMP program,” Biology of Blood and Marrow Transplantation, vol. 8, no. 4, pp. 198–205, 2002. View at Google Scholar
  24. W. P. Peters, R. D. Dansey, J. L. Klein, and R. D. Baynes, “High-dose chemotherapy and peripheral blood progenitor cell transplantation in the treatment of breast cancer,” Oncologist, vol. 5, no. 1, pp. 1–13, 2000. View at Google Scholar · View at Scopus
  25. D. A. Rizzieri, J. J. Vredenburgh, R. Jones et al., “Prognostic and predictive factors for patients with metastatic breast cancer undergoing aggressive induction therapy followed by high-dose chemotherapy with autologous stem-cell support,” Journal of Clinical Oncology, vol. 17, no. 10, pp. 3064–3074, 1999. View at Google Scholar · View at Scopus
  26. P. A. Rowlings, S. F. Williams, K. H. Antman et al., “Factors correlated with progression-free survival after high-dose chemotherapy and hematopoietic stem cell transplantation for metastatic breast cancer,” Journal of the American Medical Association, vol. 282, no. 14, pp. 1335–1343, 1999. View at Publisher · View at Google Scholar
  27. A. Schneeweiss, M. Hensel, P. Sinn et al., “Characteristics associated with long-term progression-free survival following high-dose chemotherapy in metastatic breast cancer and influence of chemotherapy dose,” Annals of Oncology, vol. 13, no. 5, pp. 679–688, 2002. View at Publisher · View at Google Scholar
  28. R. Brookmeyer and J. Crowley, “A confidence-interval for the median survival-time,” Biometrics, vol. 38, pp. 29–41, 1982. View at Google Scholar
  29. S. E. Jones, “Metastatic breast cancer: the treatment challenge,” Clinical Breast Cancer, vol. 8, no. 3, pp. 224–233, 2008. View at Publisher · View at Google Scholar · View at PubMed
  30. L. Dal Maso, A. Zucchetto, R. Talamini et al., “Effect of obesity and other lifestyle factors on mortality in women with breast cancer,” International Journal of Cancer, vol. 123, no. 9, pp. 2188–2194, 2008. View at Publisher · View at Google Scholar · View at PubMed
  31. J. J. Dignam, K. Wieand, K. A. Johnson, B. Fisher, L. Xu, and E. P. Mamounas, “Obesity, tamoxifen use, and outcomes in women with estrogen receptor-positive early-stage breast cancer,” Journal of the National Cancer Institute, vol. 95, no. 19, pp. 1467–1476, 2003. View at Google Scholar · View at Scopus
  32. S. Loi, R. L. Milne, M. L. Friedlander et al., “Obesity and outcomes in premenopausal and postmenopausal breast cancer,” Cancer Epidemiology Biomarkers and Prevention, vol. 14, no. 7, pp. 1686–1691, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  33. A. Macciò, C. Madeddu, G. Gramignano et al., “Correlation of body mass index and leptin with tumor size and stage of disease in hormone-dependent postmenopausal breast cancer: preliminary results and therapeutic implications,” Journal of Molecular Medicine, vol. 88, pp. 677–686, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  34. J. M. Jakicic, B. H. Marcus, K. I. Gallagher, M. Napolitano, and W. Lang, “Effect of exercise duration and intensity on weight loss in overweight, sedentary women: a randomized trial,” Journal of the American Medical Association, vol. 290, no. 10, pp. 1323–1330, 2003. View at Publisher · View at Google Scholar · View at PubMed
  35. A. Jemal, R. Siegel, E. Ward et al., “Cancer statistics, 2008,” CA Cancer Journal for Clinicians, vol. 58, no. 2, pp. 71–96, 2008. View at Publisher · View at Google Scholar · View at PubMed
  36. W. A. Woodward, E. A. Strom, S. L. Tucker et al., “Changes in the 2003 American joint committee on cancer staging for breast cancer dramatically affect stage-specific survival,” Journal of Clinical Oncology, vol. 21, no. 17, pp. 3244–3248, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  37. S. Braun, K. Pantel, P. Müller et al., “Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer,” New England Journal of Medicine, vol. 342, no. 8, pp. 525–533, 2000. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  38. S. A. Rabbani and A. P. Mazar, “Evaluating distant metastases in breast cancer: from biology to outcomes,” Cancer and Metastasis Reviews, vol. 26, no. 3-4, pp. 663–674, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  39. E. E. Calle, C. Rodriguez, K. Walker-Thurmond, and M. J. Thun, “Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. Adults,” New England Journal of Medicine, vol. 348, no. 17, pp. 1625–1638, 2003. View at Publisher · View at Google Scholar · View at PubMed
  40. G. K. Reeves, K. Pirie, V. Beral, J. Green, E. Spencer, and D. Bull, “Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study,” British Medical Journal, vol. 335, no. 7630, pp. 1134–1139, 2007. View at Publisher · View at Google Scholar · View at PubMed
  41. Y. -M. Song, J. Sung, and M. Ha, “Obesity and risk of cancer in postmenopausal Korean Women,” Journal of Clinical Oncology, vol. 26, no. 20, pp. 3395–3402, 2008. View at Publisher · View at Google Scholar · View at PubMed
  42. D. R. Cottam, S. G. Mattar, E. Barinas-Mitchell et al., “The chronic inflammatory hypothesis for the morbidity associated with morbid obesity: implications and effect of weight loss,” Obesity Surgery, vol. 14, no. 5, pp. 589–600, 2004. View at Publisher · View at Google Scholar · View at PubMed
  43. E. Fiorio, A. Mercanti, M. Terrasi et al., “Leptin/HER2 crosstalk in breast cancer: in vitro study and preliminary in vivo analysis,” BMC Cancer, vol. 8, article 305, 2008. View at Publisher · View at Google Scholar · View at PubMed
  44. D. Sisci and E. Surmacz, “Crosstalk between IGF signaling and steroid hormone receptors in breast cancer,” Current Pharmaceutical Design, vol. 13, no. 7, pp. 705–717, 2007. View at Publisher · View at Google Scholar
  45. S. E. Hankinson, W. C. Willett, J. E. Manson et al., “Alcohol, height, and adiposity in relation to estrogen and prolactin levels in postmenopausal women,” Journal of the National Cancer Institute, vol. 87, no. 17, pp. 1297–1302, 1995. View at Google Scholar
  46. S. Rinaldi, T. J. Key, P. H. M. Peeters et al., “Anthropometric measures, endogenous sex steroids and breast cancer risk in postmenopausal women: a study within the EPIC cohort,” International Journal of Cancer, vol. 118, no. 11, pp. 2832–2839, 2006. View at Publisher · View at Google Scholar · View at PubMed
  47. C. G. Greenman, C. H. Jagielski, and J. J. Griggs, “Breast cancer adjuvant chemotherapy dosing in obese patients: dissemination of information from clinical trials to clinical practice,” Cancer, vol. 112, no. 10, pp. 2159–2165, 2008. View at Publisher · View at Google Scholar · View at PubMed
  48. J. J. Griggs, E. Culakova, M. E. S. Sorbero et al., “Effect of patient socioeconomic status and body mass index on the quality of breast cancer adjuvant chemotherapy,” Journal of Clinical Oncology, vol. 25, no. 3, pp. 277–284, 2007. View at Publisher · View at Google Scholar · View at PubMed
  49. P. Poikonen, C. Blomqvist, and H. Joensuu, “Effect of obesity on the leukocyte nadir in women treated with adjuvant cyclophosphamide, methotrexate, and fluorouracil dosed according to body surface area,” Acta Oncologica, vol. 40, no. 1, pp. 67–71, 2001. View at Publisher · View at Google Scholar
  50. P. Jenkins, S. Elyan, and S. Freeman, “Obesity is not associated with increased myelosuppression in patients receiving chemotherapy for breast cancer,” European Journal of Cancer, vol. 43, no. 3, pp. 544–548, 2007. View at Publisher · View at Google Scholar · View at PubMed
  51. M. Colleoni, S. Li, R. D. Gelber et al., “Relation between chemotherapy dose, oestrogen receptor expression, and body-mass index,” Lancet, vol. 366, no. 9491, pp. 1108–1110, 2005. View at Publisher · View at Google Scholar · View at PubMed
  52. G. L. Rosner, J. B. Hargis, D. R. Hollis et al., “Relationship between toxicity and obesity in women receiving adjuvant chemotherapy for breast cancer: results from Cancer and Leukemia Group B study 8541,” Journal of Clinical Oncology, vol. 14, no. 11, pp. 3000–3008, 1996. View at Google Scholar
  53. J. P. Pierce, L. Natarajan, B. J. Cann, B. A. Parker, E. R. Greenberg, and S. W. Flatt, “The influence of a very high vegetable-fruit-fiber, low-fat diet on prognosis following treatment for breast cancer: results from the Women's Healthy Eating and Living (WHEL) randomized trial,” Breast Cancer Research and Treatment, vol. 106, p. S16, 2007. View at Google Scholar